BLFS
NASDAQ · Life Sciences Tools & Services
Biolife Solutions Inc
$26.04
+0.46 (+1.80%)
Financial Highlights (FY 2026)
Revenue
100.21M
Net Income
-4,784,604
Gross Margin
64.6%
Profit Margin
-4.8%
Rev Growth
-15.9%
D/E Ratio
0.01
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 64.6% | 64.6% | 54.8% | 54.8% |
| Operating Margin | -17.3% | -15.5% | 5.1% | 5.3% |
| Profit Margin | -4.8% | -4.5% | 4.6% | 6.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 100.21M | 119.17M | 1.26B | 1.01B |
| Gross Profit | 64.69M | 76.93M | 690.00M | 556.09M |
| Operating Income | -17,295,919 | -18,511,508 | 63.84M | 54.08M |
| Net Income | -4,784,604 | -5,120,874 | 58.21M | 63.51M |
| Gross Margin | 64.6% | 64.6% | 54.8% | 54.8% |
| Operating Margin | -17.3% | -15.5% | 5.1% | 5.3% |
| Profit Margin | -4.8% | -4.5% | 4.6% | 6.3% |
| Rev Growth | -15.9% | -15.9% | +9.5% | +17.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 8.41M | 8.41M | 538.01M | 550.42M |
| Total Equity | 627.71M | 627.71M | 666.68M | 636.38M |
| D/E Ratio | 0.01 | 0.01 | 0.81 | 0.86 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -17,019,662 | -19,227,826 | 80.62M | 66.64M |
| Free Cash Flow | — | — | 44.34M | 36.90M |